You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Skin Health Systems reported third-quarter net sales of $69.2 million and raised full-year 2026 adjusted EBITDA guidance to $48 million to $50 million, narrowing net sales guidance to $281 million to $287 million.
SkinHealth Systems Inc. reported nine-month 2026 net sales of $206.2 million, down 5.6%, and a $10.2 million net loss, with cash of $112.4 million. It expects refinancing, restructuring, or other capital will be needed for the $250.0 million 2028 Notes.
SkinHealth Systems Inc. effected a 1-for-20 reverse stock split at 12:00 a.m., Eastern Time on October 14, 2026, to help regain Nasdaq’s $1.00 minimum bid price compliance.
SkinHealth Systems Inc. repaid the remaining principal of its Notes in full on September 30, 2026, paying $103,235,000 plus $645,218.75 of accrued and unpaid interest; the Indenture was satisfied and discharged.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active install base | 36,516 | Three Months Ended June 30 | — |
| Adjusted EBITDA non-GAAP | $25.5M | Six Months Ended June 30 | — |
| Adjusted EBITDA margin non-GAAP | 18.6% | Six Months Ended June 30 | — |
| Adjusted gross margin non-GAAP | 72% | Six Months Ended June 30 | — |
| Adjusted gross profit non-GAAP | $98.7M | Six Months Ended June 30 | — |
| Adjusted operating expenses non-GAAP | $73.1M | Six Months Ended June 30 | — |
| Total delivery systems sold | 770 | Three Months Ended June 30 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SKIN
this stock
SkinHealth Systems Inc.
|
$106.71M | — | -10.0% | — | 5.5% |
|
PG
PROCTER & GAMBLE Co
|
$393.56B | +18.5% | +3.3% | 25.6 | 1.0% |
|
UL
Unilever PLC
|
$142.57B | +1.2% | — | — | 0.3% |
|
CL
Colgate Palmolive Co
|
$79.23B | +26.1% | +1.7% | 38.9 | 2.3% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$47.99B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SKIN | +3.8% | +54.5% | +23.6% | +64.1% | -41.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.2% | +55.6% | +23.1% | +64.3% | -52.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
